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ABSTRACT
Relapse after treatment is a common and unresolved problem for patients 
suffering of the B-cell chronic lymphocytic leukemia (B-CLL). Here we investigated 
the ability of the isopeptidase inhibitor 2cPE to trigger apoptosis in leukemia cells in 
comparison with bortezomib, another inhibitor of the ubiquitin-proteasome system 
(UPS). Both inhibitors trigger apoptosis in CLL B cells and gene expression profiles 
studies denoted how a substantial part of genes up-regulated by these compounds 
are elements of adaptive responses, aimed to sustain cell survival. 2cPE treatment 
elicits the up-regulation of chaperones, proteasomal subunits and elements of the 
anti-oxidant response. Selective inhibition of these responses augments apoptosis 
in response to 2cPE treatment. We have also observed that the product of the ataxia 
telangiectasia mutated gene (ATM) is activated in 2cPE treated cells. Stimulation 
of ATM signaling is possibly dependent on the alteration of the redox homeostasis. 
Importantly ATM inhibition, mutations or down-modulation increase cell death in 
response to 2cPE. Overall this work suggests that 2cPE could offer new opportunities 
for the treatment of B-CLL.
INTRODUCTION
B-cell chronic lymphocytic leukemia (B-CLL) is 
the most prevalent leukemia in Western countries and it 
is characterized by accumulation of malignant cells in the 
blood, lymph nodes, spleen and bone marrow. B-CLL is 
a severe disease with heterogeneous clinical course and 
although new therapies have significantly prolonged the 
overall survival, most patients relapse [1]. Augmented 
expression of anti-apoptotic Bcl-2 family members and 
up-regulation of pro-survival pathways contribute to the 
resistant phenotype [1–5].
Among drugs tested for the ability to trigger 
apoptosis in B-CLL cells, inhibitors of the ubiquitin-
proteasome system (UPS) have raised some interest. 
Bortezomib, the first UPS inhibitor approved for the use 
in clinic, efficiently triggers apoptosis in in vitro cultured 
B-CLL cells [6, 7]. Unfortunately, clinical trials evaluating 
bortezomib in B-CLL patients were unsatisfactory [8]. 
Several constrains can explain this failure, including 
the chemical reaction between the boronate moiety of 
bortezomib and dietary flavonoids [9]. Furthermore 
bortezomib induces thrombocytopenia and neuropathy 
possibly due to proteasomal independent activities [10]. 
Hence, evaluating alternative compounds targeting the 
UPS for the treatment of B-CLL is of primary importance.
Small molecules characterized by the presence 
of a cross-conjugated α,β-unsaturated dienone with 
two sterically accessible electrophilic β-carbons can 
act as Michael acceptors to target nucleophiles, such 
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as cysteine residues [11–14]. Highly susceptible to 
these compounds are the isopeptidases, which contain 
a cysteine in the catalytic core. Isopeptidases include 
DUBs (deubiquitylases) and ubiquitin-like proteases. 
Although the presence of different groups, in addition to 
the pharmacophore, can enhance or limit the promiscuity 
of these compounds, we refer to them as partially-selective 
isopeptidase inhibitors (P-SIIs) [11–16].
P-SIIs are potent inducers of apoptosis and of 
additional types of cell death, particularly in cells 
showing extreme apoptotic resistance [17–19]. We have 
recently developed a PEG-conjugated P-SII, named 2cPE 
optimized for the in vivo delivery. 2cPE is a pro-drug 
version of G5 [11], which can be activated by secreted 
esterase and exhibits promising anti-neoplastic activities 
in vivo [20]. In this manuscript, we have investigated the 
effect of 2cPE against B-CLL cells, in comparison with 
bortezomib. Our results prove that induction of proteotoxic 
stress is a key aspect of 2cPE activity and discovered an 
unexpected contribution of ATM in influencing 2cPE-
induced apoptosis.
RESULTS
The UPS inhibitors bortezomib, G5 and 2cPE 
cause loss of viability of CD19+ B-CLL cells
Bortezomib and the isopeptidase inhibitor G5, or 
its PEGylated derivative 2cPE, induce loss of viability in 
primary CLL cells (Figure 1A and 1B). Cytofluorimetric 
analysis proved that, for all inhibitors, the loss of viability 
is largely caused by the induction of apoptosis, with only a 
minor fraction of the cells exhibiting markers (Annexin-V- 
and PI+) of primary necrosis (Figure 1C and 1D).
Gene expression profiles of B-CLL cells treated 
with the UPS inhibitors bortezomib and 2cPE
To explore whether bortezomib and 2cPE elicit 
similar or different biological responses, we performed 
microarray experiments in primary B-CLL cells. Leukemia 
CD19+ B-cells from 10 different patients were treated or 
not for 3, 6, 12 and 24 hours with 6nM of bortezomib 
or with 4μM of 2cPE. Under these conditions the two 
compounds induce equivalent levels of apoptosis, at 24 
hours. For the microarray analysis the 6 hours time-point 
was selected in order to observe early adaptive responses 
to the inhibitors and to exclude changes in mRNA 
expression depending on cellular demise. The clinical 
and prognostic features of each of the 10 primary CLL 
samples and their responsiveness in terms of apoptosis are 
described in Table 1.
Data analysis identified a list of common genes, 
which expression is influenced by both compounds. Venn 
diagrams (Figure 2A) illustrate that only few genes were 
commonly modulated by 2cPE and bortezomib in different 
patients (19 up-regulated and 15 down-regulated). Overall 
2cPE influences the expression of a wider number of genes 
compared to bortezomib, 169 and 95 genes respectively, 
including both up and down-regulated ones.
The vast majority of the commonly up-regulated 
genes encode for chaperones implicated in the regulation 
of protein folding (Figure 2B). A second group of genes 
comprises proteasome subunits. Interestingly among the 
commonly down-regulated genes, metabolic elements and 
components of signaling pathways can be found.
It is known that the level of proteasomal subunits 
can influence responsiveness to bortezomib treatment 
[21–23]. Hence, we compared changes in the expression 
levels of all proteasomal genes. Up-regulation of mRNAs 
encoding for several proteasomal subunits is a mark of 
the response to both inhibitors. This response was more 
pronounced in the case of bortezomib, whereas the down-
regulation of the immunoproteasome subunits PSMB8, 
PSMB9 and PSMB10 was comparable or even more 
evident in 2cPE treated cells.
The GO enrichment analysis for 2cPE and bortezomib 
regulated genes (Table 2) showed that the two drugs can elicit 
common but also distinct responses. Over-representations 
of processes such as protein folding, response to unfolded 
protein and response to organic substance characterize 
the genetic programs activated by 2cPE. Instead after 
bortezomib treatment, proteasome complex and regulation 
of E3 ligase activity are the most represented categories. 
Comparative analysis of the GO terms enrichment confirmed 
that the response to 2cPE treatment is strongly characterized 
by the up-regulation of chaperones, whereas the response 
to bortezomib is highly represented by UPS components 
(Supplementary Table S1).
Adaptive responses are engaged in B-CLL cells 
after 2cPE treatment
The microarray studies suggest that a substantial part 
of genes up-regulated in response to 2cPE are elements of 
adaptive programs aimed to sustain cell survival. These 
programs include the accumulation of new proteasomal 
units, to overcome its obstruction, the up-regulation of 
chaperones, to counteract misfolding and the potentiation 
of the anti-oxidant capabilities. In addition, 2cPE triggers 
also the down-regulation of some signaling pathways. To 
validate our studies we performed qRT-PCR analysis on 
four different genes, archetypes of the adaptive responses 
engaged by 2cPE. Three selected genes were up-regulated: 
GCLM, HMOX1, SQSTM1/p62, whereas the fourth gene, 
LCK, was down-regulated. Supplementary Table S2 shows 
the average fold induction and the correlation analysis, 
respect to the induction of apoptosis in the different 
B-CLL, for these genes.
GCLM (glutamate cysteine ligase modifier) encodes 
for the component of the glutamate cysteine ligase (GCL), 
the enzyme responsible for glutathione (GSH) synthesis. 
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Both subunits were increased after 2cPE treatment. The 
heme oxygenase-1 (HMOX1) encodes for an ubiquitous 
enzyme that supervises cytoprotective responses to toxic 
insults [24]. SQSTM1/p62/sequestosome encodes for a 
scaffold protein functioning as signaling hub in different 
pathways including autophagy [25]. Finally, LCK encodes 
for the T-cell-specific member of the Src family of tyrosine 
kinase, which is also expressed in B-CLL [26]. The qRT-
PCR analysis corroborated the regulation of these genes 
in response to 2cPE treatment (Supplementary Figure S1).
We next confirmed these data in human chronic 
B-cell leukemia, MEC-1 cells. The 2cPE pro-drug and 
its unconjugated version, 2c induce comparable levels of 
cell death (Figure 3A), thus indicating that this cell line 
Figure 1: Pro-apoptotic activity of bortezomib, the P-SII G5 and its pro-drug derivative 2cPE in primary B-CLL 
cells. A. Primary B-CLL cells viability following treatment with escalating doses of G5 or bortezomib for 24 hours as indicated. Cell 
viability was calculated as percentage of cells negative to PI and Annexin V staining after cytofluorimetric analysis. B. Flow cytometry 
analysis for apoptotic markers (Annexin V/PI) in order to define the type of cell death. Primary B-CLL cells were treated with the indicated 
concentrations of bortezomib or G5 for 24 hours. C. Primary B-CLL cells viability following treatment with escalating doses of 2cPE for 
24 hours as indicated. Cell viability was calculated as the percentage of cells negative to PI and Annexin V staining after cytofluorimetric 
analysis. D. Flow cytometry analysis for apoptotic markers (Annexin V/PI) in order to define the type of cell death. Primary B-CLL 
cells were treated with the indicated concentrations of 2cPE for 24 hours. Columns, mean loss of viability + SD. *=p<0.05; **=p<0.01; 
***p=<0.005.
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secretes the esterase PLA2G7 [20]. 2c and 2cPE induced 
cell death was apoptotic, as confirmed by the caspase-
dependent proteolytic cleavage of the death substrate 
GAS2 (Figure 3B) [27]. In MEC-1 cells, similarly to 
primary B-CLL cells, 2cPE treatment up-regulates the 
expression of HMOX1, GSLM as well as of SQSTM1 and 
down-regulates LCK mRNA levels (Figure 3C).
HMOX1, GCLM and SQSTM1 are components 
of the cytoprotective response to oxidative stress and, 
likewise other genes induced after 2cPE treatment, they 
are under the control of the transcription factor NRF2 [28, 
29]. Figure 3D proves that 2cPE treatment augmented 
NRF2 levels in MEC-1 cells.
Inhibition of the adaptive responses elicited by 
2cPE and effects on cell death
Several of 2cPE differentially expressed genes 
(DEGs) boost adaptive responses devoted for sustaining 
cell survival. Hence, suppressing these adaptive responses 
should potentiate apoptosis in response to 2cPE. To verify 
this hypothesis we co-treated MEC-1 cells with 2cPE 
in combination with buthionine sulfoximine (BSO), a 
selective inhibitor of γ-glutamylcysteine synthetase, or 
with the geldanamycin derivative 17-AAG, an inhibitor 
of HSP90. BSO alone was unable to trigger cell death 
but at highest doses it potentiated the pro-death effect of 
2cPE, as scored by both PI positivity and caspase activity 
(Figure 4A). When the ROS generator DMNQ was 
used, as positive control, the cooperative effect of BSO 
was more evident (Figure 4A). Treatment with 17-AGG 
alone induces apoptosis in approximately 30% of cells, 
independently from the applied dose. When MEC-1 cells 
pre-incubated with escalating doses of 17-AGG were co-
treated with 2cPE, cell death as well as the intensity of 
caspase activation, were significantly augmented (Figure 
4B). Similarly, also bortezomib induced cell death was 
augmented in the presence of the HSP90 inhibitor (Figure 
4B).
Down-regulation of LCK expression might be an 
important event for the pro-apoptotic activity of 2cPE. 
Also in this case treatment with an LCK inhibitor (LCKi) 
might exhibit an additive effect with 2cPE. Figure 
3C evidences that co-treatment with 2cPE and LCKi 
potentiates apoptosis and caspase activation in response 
to 2cPE.
Markers of responsiveness to 2cPE treatment
The apoptotic responsiveness of B-CLL cells from 
the different patients to 2cPE is heterogeneous (Table 1). 
Some cells are highly susceptible and others are resistant. 
Hence, we decided to use the pattern of all DEGs in all 
patients to discover markers of 2cPE responsiveness. The 
lists of DEGs were fused and used to extract the values 
of single patient differences (fold changes >1.5 <-1.5; 
P values <0.05). An unsupervised clustering analysis 
was performed and the results are presented as heat map 
(Figure 5). The apoptotic responsiveness of the different 
leukemic B-cells is displayed by a colour code. The 
Table 1: Clinical characteristics, apoptotic response, mutational status and genetic alterations of the included 
patients
code Sex/age IGHV FISH RAI stage CD38 2cPE Bortezomib
LL300 F/79 U 13q- II NEG 88 89
LLC122 M/66 U 11q- 0 POS 15 59
LLC195 M/69 U 11q-; 13q- II POS 2 86
LLC351 M/67 U 17q-; 13q- I POS 81 92
LLC270 M/73 U 11q- II POS 17 65
LLC4 F/73 M * I NEG 82 81
LLC305 M/56 M Normal 0 NEG 75 54
LLC366 F/69 * 13q-; 12+; p53 mut 0 POS 45 77
LLC37 F/79 M 13q- II NEG 8 38
LLC43 M/83 M 12+ I POS 68 82
 Apoptosis at 24 hours (%)
Note: The gender of the patients, the IgHV mutational status (U=unmutated, M= mutated), CD38 expression (POS = 
positive for CD38 expression; NEG = negative CD38 expression), the cytogenetic alterations observed and the % of 
apoptosis after 24 of treatment with the indicated drugs for each patient sample are shown. 
* indicates that the status of a specific characteristic for a patient is unknown.
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Figure 2: mRNA expression profiling of bortezomib and 2cPE treated B-CLL cells. A. Venn diagram of commonly down 
(green) and up-regulated (blue) genes (fold changes >1.5; P values <0.01) using the paired t-test, in leukemic B-cell from 10 different 
patients after 2cPE and bortezomib treatments. B. List in alphabetic order of the commonly up- and down-regulated genes in leukemic 
B-cells form the different patients in response to 2cPE and bortezomib treatments (mRNA fold changes >1.5; <-1.5). In the heat map 
positive values are displayed in blue and negative in dark green. A colour code was selected to illustrate the fold changes. C. mRNA fold 
changes of the different proteasomal components after 2cPE and bortezomib treatments as indicated by the different colours.
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hierarchical clustering evidences a strong correlation 
between the magnitude of changes in DEGs and the 
induction of cell death. In the case of 2cPE treatment, with 
the exclusion of patient LLC37, all B-CLL cells responsive 
to 2cPE in terms of apoptosis, cluster together and show 
elevated fluctuations of DEGs. On the other side, B-CLL 
cells, which are resistant to 2cPE treatment evidence 
fewer transcriptional changes and cluster together. The 
only exception concerns leukemic cells of patient LLC37, 
which are resistant to 2cPE treatment but cluster together 
with responsive cells. Interestingly, LLC37 cells are also 
partially resistant to bortezomib.
Resistance to 2cPE induced apoptosis in B-CLL 
cells from patients LLC122, LLC195 and 
LLC270
The resistance to 2cPE-induced apoptosis, 
observed in some leukemia B-cells (LLC122, LLC195 
and LLC270) is tightly correlated to much lower 
variations in the transcriptome. This failure could arise 
from an incapability to process the pro-drug 2cPE in the 
extracellular environment, as observed in certain cancer 
cells [20]. mRNA expression levels analysis of PLAG7, 
the secreted esterase responsible for 2cPE pro-drug 
maturation, excludes this hypothesis (Supplementary 
Figure S2).
Alternatively, resistance to 2cPE could arise from 
a common mRNA signature, as generated during disease 
progression, through the accumulation of peculiar 
genetic alterations. This signature should predict drug-
responsiveness. To verify this possibility, we performed 
hierarchical gene clustering analysis, of gene expression 
profiles of untreated B-CLL cells from all patients. Figure 
6A shows that, the B-CLL cells of the three patients 
resistant to 2cPE treatment cluster together. Next, a 
standard t-test was performed to rank DEGs between 2cPE 
unresponsive (n3) and the responsive leukemia cells (n7) 
(Figure 6B). The ATM gene provided the best score (P 
value 2.9306E-005; fold change -1.87). In accordance, 
all three patients-derived B-CLL cells display the 11q 
deletion, which affects the ATM locus [30]. Other two 
genes, NPAT and CUL5 lie in the same chromosome 
region and they also scored a significant reduction in 
terms of expression in the non-responsive patients (P 
value 0.0035; fold change -1.69 and P value 0.0020; fold 
change -1.64, respectively).
Table 2: GO-Terms enrichment analysis
Gene enrichment analysis in 2cPE treated primary B-CLL cells
GO-Term Count % p Value Benjamini FDR Fold Enr
GO:0006986~response  
to unfolded protein 13 8,33 1,66E-12 2,67E-09 2,78E-09 19,82
GO:0051789~response  
to protein stimulus 13 8,33 3,90E-07 1,96E-07 4,08E-07 13,15
GO:0050865~regulation 
of cell activation 14 8,97 7,16E-09 3,84E-06 1,20E-05 8,66
GO:0010033~response  
to organic substance 25 16,02 3,11E-08 1,25E-05 5,21E-05 3,75
GO:0006457~protein 
folding 13 8,33 7,73E-08 1,75E-05 0,00013 7,94
GO:0042981~regulation 
of apoptosis 25 16,02 2,38E-07 4,80E-05 0,0004 3,37
Gene enrichment analysis in Bortezomib treated primary B-CLL cells
GO-Term Count % p Value Benjamini FDR Fold Enr
GO:0000502~proteasome 
complex 14 15,73 4,31E-18 5,26E-16 4,97E-15 42,52
GO:0051351~positive 
regulation of ligase 
activity
15 16,85 1,35E-18 1,16E-15 2,09E-15 37,56
GO:0043161~proteasomal 
protein catabolic process 15 16,85 1,91E-16 1,91E-14 3,44E-13 26,88
Oncotarget45435www.impactjournals.com/oncotarget
Figure 3: Adaptive responses elicited by 2cPE in MEC-1 cells. A. Induction of cell death in MEC-1 cells after treatment for the 
indicated times with 2c (2μM) or 2cPE (4μM). Cell viability was calculated as percentage of cells positive to PI staining using cytofluorimetric 
analysis. B. Caspase-dependent processing of the death substrate Gas2 in MEC-1 cells treated for the indicated times with 4μM of 2cPE. 
Cellular lysates were generated and subjected to immunoblot analysis. Antibodies anti-Gas2 and anti-actin (as loading control) were used. 
C. Time-course analysis of HOMX, GCLM, SQSTM and LCK mRNA expression levels. MEC-1 cells were treated 4μM of 2cPE for the 
indicated times and the mRNA levels were monitored by qRT-PCR. All reactions were done in triplicate. D. Immunoblot and densitometric 
analysis of NRF2 levels in MEC-1 cells treated for the indicated times with 4μM of 2cPE. Cellular lysates were generated and subjected 
to immunoblot analysis using the indicated antibodies. Data were from 2 experiments. Columns, mean loss of viability + SD. *=p<0.05; 
**=p<0.01; ***p=<0.005.
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Since ATM is an important signaling molecule, 
we decided to study whether this kinase is activated in 
response to 2cPE. Figure 7A demonstrates that the ATM 
pathway is activated in response to 2cPE, as proved by 
the phosphorylation of the ATM substrates KAP1, Smc1, 
Chk2 and p53. The 2cPE-mediated activation of ATM 
prompted us to evaluate the induction of DNA double-
strand breaks. Different concentrations of etoposide 
were used to induce DSBs and ATM activation. 4μM 
of 2cPE and 2.5/5 μM of etoposide elicited ATM 
activation at comparable intensities, as scored by KAP1 
phosphorylation (Figure 7B). A robust increase of γH2AX 
positivity (a marker of DSBs) can be appreciated in cells 
treated with 2.5 or 5 μM of etoposide. By contrast, only a 
modest but significant increase in γH2AX positivity was 
triggered by 2cPE treatment (Figure 7C). We confirmed 
these data by a time-course analysis. Again a modest, 
compared to etoposide, but significant increase in γH2AX 
was detectable in 2cPE treated cells at 6 hour (Figure 7D).
Next we investigated the contribution of ATM in 
2cPE-induced gene expression changes. Inhibition of 
the ATM kinase using the specific inhibitor KU-55933 
did not influenced the 2cPE-mediated up-regulation 
of GCLM, HOMX, SQSTM1 and the down-regulation 
Figure 4: Interfering with the different adaptive responses elicited by 2cPE augmented the apoptotic response. A. MEC-
1 cells were pre-treated with the indicated concentrations (μM) of BSO, for 24 h. Next, 2cPE (1μM), DMNQ (20μM) were added for further 
24 h. B. MEC-1 cells were pre-treated with the indicated concentrations (μM) of 17-AAG for 1 h. Next, 2cPE (1μM), bortezomib (0.5 μM) 
were added for further 24 h. C. MEC-1 cells were pre-treated with the indicated concentrations (μM) of LCKi for 16 h. Next, 2cPE (1μM), 
bortezomib (0.5 μM) were added for further 24 h. Cell death was scored by PI staining using cytofluorimetric analysis and caspase activity 
was measured in parallel. Columns, mean (n = 3); bars, SD. *=p<0.05; **=p<0.01; ***p=<0.005.
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of LCK (Figure 7E). Surprisingly, when the effect on 
cell survival was evaluated, the ATM inhibitor strongly 
potentiated apoptosis in response to 2cPE (Figure 8A). 
To confirm this result we used ataxia telangiectasia (AT)-
derived lymphoblastoid cell lines (AT-LCLs) WT or 
lacking ATM protein expression, due to the homozygous 
mutation AT-52RM [31]. Figure 8B illustrates that cells 
lacking ATM expression are more sensitive to death 
induced by 2cPE treatment. Finally, we also generated 
MEC-1 cells with down-regulated ATM expression 
after lentiviral infections with a specific shRNA (Figure 
8C). MEC-1 cells with down-regulated ATM were 
more susceptible to apoptosis after 2cPE treatment 
(Figure 8D).
Figure 5: Resistance to 2cPE induced apoptosis correlates with the magnitude of changes in DEGs. DEGs induced by 
2cPE or bortezomib treatments in B-CLL cells were hierarchically clustered as described in the material and methods. In the heat map 
up-regulated genes are displayed in blue and down-regulated genes in dark green. A colour code was used to represent the apoptotic 
responsiveness to 2cPE and bortezomib of the different B-CLL cells. Apoptosis >75% (dark green); apoptosis between 46-74% (light 
green) apoptosis <20% (grey) apoptosis <10% (black).
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Figure 6: ATM and the resistance to 2cPE. A. Hierarchical clustering of gene expression profiles of untreated B-CLL cells from the 
different patients. A colour code was used to represent the apoptotic responsiveness to 2cPE and bortezomib of the different B-CLL cells. 
Apoptosis >75% (dark green); apoptosis between 46-74% (light green) apoptosis <20% (grey) apoptosis <10% (black). B. 10 top DEGs in 
untreated B-CLL cells from patients LLC122, LLC195 and LLC270 compared to the untreated leukemia cells, responsive to 2cPE, from all 
other patients. DEGs were ranked for P value.
Figure 7: 2cPE activates ATM signaling. A. Activation of the ATM signaling pathway in response to 2cPE treatment. Cellular 
lysates were generated at the indicated time points and subjected to immunoblot analysis. The detected proteins and their phosphorylated 
forms are indicated. Actin was used as loading control. B. Immunoblot analysis comparing ATM activation in response to etoposide and 
2cPE. KAP1 phosphorylation was used as read-out for ATM activation. MEC-1 cells were treated for 6 h with the indicated concentrations 
of the two drugs. C. Quantitative cytofluorimetric analysis of γH2AX positivity as marker of DNA damage induction. MEC-1 cells were 
treated for 6 hours with the indicated concentrations of the two drugs. D. Time-course of γH2AX positivity by quantitative cytofluorimetric 
analysis. MEC-1 cells were treated for the indicated hours with 4μM of 2cPE or 2.5μM of etoposide. E. Time-course analysis of HOMX, 
GCLM, SQSTM and LCK mRNA expression levels in MEC-1 cells treated with 4μM of 2cPE in the presence of the ATM inhibitor KU-
55933. Cells were pre-treated for 1 hour with KU-55933 (10μM), next, 2cPE was added for further 6 h. Columns, mean (n = 3); bars, SD. 
*=p<0.05; **=p<0.01; ***p=<0.005.
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DISCUSSION
Although bortezomib has proved inefficacy for 
the treatment of CLL patients [8], the UPS represents a 
promising therapeutic target and new UPS inhibitors are 
under evaluation [32–34]. In this manuscript we have 
demonstrated that 2cPE triggers apoptosis in B-CLL cells 
and activates multiple transcriptional programs.
The vast majority of DEGs associated to 2cPE 
and bortezomib treatments encode for elements of 
stress response pathways, aimed to sustain cell survival. 
Interfering with such adaptive pathways potentiates the 
pro-death effect of 2cPE. This discovery could help to 
improve the anti-neoplastic efficiency of these molecules, 
by applying selective co-treatments.
Interestingly 2cPE is a stronger inducer of 
proteotoxic stress compared to bortezomib. Proteotoxic 
stress is emerging as an attracting druggable response. 
Malignant cells exhibit higher levels of proteotoxic 
stress, as a consequence of their higher proliferative and 
mutational status [35–38]. This peculiarity renders cancer 
cells more dependent on the UPS and more vulnerable 
Figure 8: ATM inhibition strengthens apoptosis induced by 2cPE. A. MEC-1 cells were pre-treated for 1 hour with KU-55933 
(10μM). Next, 2cPE (2μM) or camptothecin (CTP) (50μM) were added for further 20 h. Cell death was calculated as percentage of cells 
positive to PI staining using cytofluorimetric analysis. B. LCL cells WT or AT-52 mutated were treated for 22 h with 2μM of 2cPE. Cell 
death was scored by PI staining using cytofluorimetric analysis. C. ATM mRNA levels in MEC-1 cells expressing the shRNA against ATM 
or the control, as generated by two distinct lentiviral infections. D. MEC-1 cells with down-regulated ATM expression generated after two 
distinct infections (A and B) and control cells were treated with 2cPE (0.5μM) for 6 h. Cell death was calculated as percentage of cells 
positive to PI staining using cytofluorimetric analysis. Columns, mean (n = 4); bars, SD. *=p<0.05; **=p<0.01; ***p=<0.005.
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to its inhibitors or to inducers of proteotoxic stress [39, 
40]. We propose that 2cPE and similar compounds are 
efficient anti-neoplastic drugs in vivo, because they elicit 
a vicious cycle, by triggering proteotoxic stress in cancer 
cells, which already exhibit high level of such stress. By 
contrast, 2cPE-induced proteotoxic stress is manageable 
in normal cells, thus explaining the absence of general 
toxicity in vivo [40–42]. It is possible that 2cPE and 
similar compounds, in addition of targeting the catalytic 
cysteine of isopeptidases, react with and consume the 
glutathione pool, thus provoking oxidative-stress. In fact, 
NRF2 is activated and the GSH regenerating system is up-
regulated in response to 2cPE. Moreover, pre-treatment 
of G5 with N-acetylcysteine completely abrogates its 
apoptotic activity (data not shown).
Because of the heterogeneity of this disease [43], 
some leukemia cells are resistant to 2cPE treatment. 
Gene expression profile analysis indicates two different 
conditions of resistance. In the first case, cells display 
overt changes in DEGs associated to 2cPE (patient 
LLC37). In the second case, which comprises leukemia 
cells from patients LLC122, LLC195 and LLC270, DEGs 
changes are dramatically reduced.
The components of the apoptotic machinery in 
LLC37 cells, (BCL2 family members and caspases) do not 
evidence alterations in their expression (data not shown). 
Hence, currently we cannot explain the origin of such 
resistance. Importantly, LLC37 cells were analogously 
resistant to bortezomib.
In leukemia cells from patients LLC122, LLC195 
and LLC270, resistance is not due to deficit in pro-drug 
maturation, as recently observed in other cancer cells [20]. 
Hierarchical gene clustering analysis of the different patient-
derived B-CLL cells and the presence of the 11q deletion 
suggested that ATM could be a candidate for such resistant 
phenotype. The ATM kinase has a well-defined role in 
sensing DNA double-strand breaks (DSB) and transducing 
downstream signals that activate the DNA repair and the 
cell cycle checkpoint machinery [44]. Notably, the ATM 
signaling pathway was stimulated by 2cPE.
ATM is also activated by oxidative stress, through 
a mechanism distinct to that of activation by DNA breaks 
[45]. The activation of the anti-oxidants response and the 
feeble appearance of DSBs in 2cPE treated cells, suggest 
that a perturbed redox balance might be responsible for 
ATM activation [46]. In an unexpected manner, ATM 
inhibition reinforced apoptosis in 2cPE treated cells. 
Hence, ATM cannot be responsible for the apoptotic 
resistance to 2cPE. Although we do not have an explanation 
for such resistance, our results disclose a new opportunity 
for testing 2cPE in cancer cells that have accumulated 
mutations in ATM, in p53, or in both genes [47, 48].
In conclusion we have demonstrated that 2cPE 
triggers pleiotropic cellular stresses. At first glance 
induction of multiple stresses does not seem to be 
attractive for the selective elimination of neoplastic cells, 
however several recent reports about the effectiveness in 
animal models of this class of compounds [12, 14, 15, 
20] justify further studies to improve their anti-neoplastic 
activities.
MATERIALS AND METHODS
Patients, cell separation and culture conditions
The ethic approval for our study was obtained from 
ethic committee of ‘‘Regione Veneto”: (Prot.n. 2662P). We 
obtained peripheral blood from 10 patients that satisfied 
standard morphological and immunophenotypic criteria 
for CLL according to the guidelines of the International 
Workshop on Chronic Lymphocytic Leukemia IWCLL 
[49]. No patient was previously treated with bortezomib or 
other proteasome inhibitors. Peripheral blood mononuclear 
cells (PBMCs) were isolated as previously described [50]. 
All samples utilized had a CD19+ B-cell content greater 
than 95%. Purified cells were cultured in RPMI-1640 
medium supplemented with 10% heated inactivated fetal 
calf serum (FCS; Invitrogen, Paisley, UK). Human chronic 
B-cell leukemia, MEC-1 cells and EBV-immortalized 
lymphoblastoid cell lines (LCLs) WT and AT52RM and 
compound heterozygous mutations 7626 C→T/8365 del 
A, were grown under similar conditions. Mediums were 
supplied with heated inactivated fetal calf serum (FCS; 
Sigma Aldrich), penicillin (100 U/mL), glutamine (2 
mmol/L), and streptomycin (100 μg/mL).
Reagents and antibodies
Chemicals used were: bortezomib (LC 
Laboratories), 2,3-dimethoxy-1,4-naphthoquinone 
(DMNQ), Propidium Iodide (Sigma Aldrich), buthionine 
sulfoximine (BSO), 7-cyclopentyl-5-(4-phenoxyphenly)-
7H-pyrrolo[2,3-d]pyrimidin-4-amine LCK inhibitor 
(LCKi), 17-(Allylamino)-17-demethoxygeldanamycin 
(17-AAG) (Cayman Chemicals), ATM inhibitor (KU-
55933) (Abcam Biochemicals), 2c ((E)-3,5-Bis[(p-
nitrophenyl)methylidene]-4-hydroxycyclohexanone), 
2cPE ((E)-3,5-Bis[(p-nitrophenyl)methylidene]-4-
oxocyclohexyl polyethyleneglycol succinate). Primary 
antibodies used were: anti-phospho-Ser139 H2A.X, 
anti-pKAP-1/TIF1β Ser824 and anti-KAP1/TIF1β (Cell 
Signaling), anti-actin (a2066 Sigma) anti-NRF2 (Santa 
Cruz Biotechnology).
RNA expression array and data analysis
Total RNA was isolated using RNeasy Mini 
kit (Qiagen). RNA samples concentration and purity 
(assessed as 260/280 nm and 260/230 nm ratios) were 
evaluated by NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies; Wilmington, DE), while 
RNA integrity was assessed by using the Agilent 
2100 Bioanalyzer (Agilent Technologies; Waldbrunn, 
Germany). For gene expression profiling (GEP) cDNA 
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synthesis and biotin-labeled target synthesis were 
performed using the GeneAtlas 3′ IVT Express Kit 
according to the protocol supplied by Affymetrix. The 
HG-U219 Array Strips (Affymetrix; Santa Clara, CA) 
hybridization, staining, and scanning were performed 
by using the GeneAtlas Platform. All the GEP data 
have been deposited in the NCBI's Gene Expression 
(GEO) public repository http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=kbapyckufpcdxwh&ac
c=GSE74514. Data analysis was performed using the 
paired t-test as previously described [51]. P values were 
adjusted for multiple testing using the False Discovery 
Rate method. Differentially expressed genes (DEGs) 
were selected based on fold change >1.5 and <-1.5 fold 
and P values <0.05. The analysis of Gene Ontology 
terms was performed using the DAVID server. DEGs 
in response to 2cPE or bortezomib were clustered using 
hierarchical clustering by computing the Euclidean 
distance and applying the complete linkage method. 
For the hierarchical clustering of the gene expression 
profiles of B-CLL cells from different patients before 
drug-treatment the average linkage method was used.
RNA extraction and qRT-PCR analysis
RNA was extracted using Tri-Reagent (Molecular 
Research Center) and retrotranscribed by using 100U of 
Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). The primer sequences used are available 
upon request. Quantitative reverse transcription-PCR 
(qRT-PCR) analyses were performed using Bio-Rad 
CFX96 and SYBR Green technology. HPRT and GAPDH 
were used as normalizer genes. All reactions were done 
in triplicate. Data were from al least 3 experiments ± SD.
Caspase activation assays and cytofluorimetric 
analysis
Analysis of caspase-3 activation was performed 
using Caspase-3 fluorescent assay kit (Cayman chemical). 
For quantification of cell death, cells were re-suspended 
in 500 μL of PBS and stained with propidium iodide 
(PI). Fluorescence was determined with a FACScan™ 
(Beckman Dickinson). To detect H2AX phosphorylation 
cells were fixed in paraformaldehyde 3% for 20’ at room 
temperature, permeabilized with 0.1% TritonX-100 and 
incubated with the primary antibody anti-pH2AX for 1hr. 
After washes, cells were incubated with the secondary 
antibody anti-rabbit Alexa Fluo-488 (Invitrogen) for 30 
min. Results were from al least 3 experiments ± SD.
Western blotting and lentiviral infections
Proteins obtained after an SDS denaturating lysis 
and sonication were transferred to nitrocellulose membrane 
and incubated with the specific primary antibodies. 
Secondary antibodies were peroxidase-conjugated goat 
anti-rabbit or anti-mouse (Sigma). Blots were developed 
with Super Signal West Dura (Pierce). For stable ATM 
down-regulation, the vector-based shRNA interference 
pLenti6/BLOCK-iT-DEST (Invitrogen) was used as 
previously described [52]. Culture supernatant obtained 
from transfected recipient 293 cells, containing viral 
particles, was recovered and used to infect MEC-1 cells.
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